159 related articles for article (PubMed ID: 36197194)
1. Performance of Remsima® Monitor Drug Level versus RIDASCREEN IFX Monitoring in therapeutic drug monitoring of infliximab in patients with inflammatory bowel disease: A study of diagnostic accuracy.
Song JH; Hong SN; Kim ER; Chang DK; Kim YH
Medicine (Baltimore); 2022 Sep; 101(38):e30683. PubMed ID: 36197194
[TBL] [Abstract][Full Text] [Related]
2. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
3. Experience with Biosimilar Infliximab (Remsima®) in Norway.
Jahnsen J; Kaasen Jørgensen K
Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
[TBL] [Abstract][Full Text] [Related]
4. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
[TBL] [Abstract][Full Text] [Related]
5. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ
Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar infliximab use in paediatric IBD.
Richmond L; Curtis L; Garrick V; Rogers P; Wilson M; Tayler R; Henderson P; Hansen R; Wilson DC; Russell RK
Arch Dis Child; 2018 Jan; 103(1):89-91. PubMed ID: 28988215
[TBL] [Abstract][Full Text] [Related]
7. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
Buer LC; Moum BA; Cvancarova M; Warren DJ; Medhus AW; Høivik ML
J Crohns Colitis; 2017 Mar; 11(3):297-304. PubMed ID: 27660339
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
[TBL] [Abstract][Full Text] [Related]
9. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
13. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
Villemonteix J; Guérin-El Khourouj V; Hugot JP; Giardini C; Carcelain G; Martinez-Vinson C
Biologicals; 2021 Apr; 70():17-21. PubMed ID: 33676831
[TBL] [Abstract][Full Text] [Related]
16. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade
Xue L; van Bilsen K; Schreurs MWJ; van Velthoven MEJ; Missotten TO; Thiadens AAHJ; Kuijpers RWAM; van Biezen P; Dalm VASH; van Laar JAM; Hermans MAW; Dik WA; van Daele PLA; van Hagen PM
Front Med (Lausanne); 2020; 7():418. PubMed ID: 32850911
[No Abstract] [Full Text] [Related]
17. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
Bertin D; Serrero M; Grimaud JC; Desjeux A; Desplat-Jégo S
Cytokine; 2020 Feb; 126():154859. PubMed ID: 31629989
[TBL] [Abstract][Full Text] [Related]
18. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of persistence, retention "rate" and prescription pattern of original infliximab and infliximab CT-P13 in biologic-naïve patients with ulcerative colitis.
Valcuende-Rosique A; Borrás-Blasco J; Martínez-Badal S; Cortes X; Aparicio-Rubio C; Casterá-Melchor E
Farm Hosp; 2022 Jun; 46(5):296-300. PubMed ID: 36183230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
